Actively Recruiting
Ischemic Postconditioning in STEMI Patients Treated With Primary PCI
Led by Rigshospitalet, Denmark · Updated on 2026-03-30
1800
Participants Needed
1
Research Sites
730 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In a prospective, randomized clinical trial the iPOST2 trial will determine whether ischemic postconditioning reduces reperfusion injury and this will translate into improved clinical outcome of heart failure and death for STEMI patients who present with TIMI0-1 undergoing primary PCI
CONDITIONS
Official Title
Ischemic Postconditioning in STEMI Patients Treated With Primary PCI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 6518 years
- Acute onset of chest pain with less than 12 hours duration
- STEMI characterized by 2 mm ST elevation in 2 or more V1 through V4 leads or presumed new left bundle branch block with minimum of 1 mm concordant ST elevation or 1 mV ST-segment elevation in limb leads (II, III, aVF, I, aVL) and V4-V6 or ST depression in 2 or more V1 through V4 leads indicating posterior AMI
- TIMI flow 0-1 in infarct related artery
You will not qualify if you...
- Potential pregnancy
- Refusal to participate
- Out-of-hospital cardiac arrest without subsequent consciousness despite return of spontaneous circulation
- Thrombectomy considered unavoidable
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Heart Center, Rigshospitalet, University of Copenhagen
Copenhagen, Denmark, 2100
Actively Recruiting
Research Team
T
Thomas Engstrøm, DMSci
CONTACT
J
Jacob Lønborg, DMSci
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here